Fig. 3
NFT appear to precede NP in hippocampus but follow NP in cortical regions. a Quantification of NFT count (NFT/mm2) in hippocampus all regions, frontal cortex, and occipital cortex. NFT count, along with non-NP and NP count is quantified from the same sample using modified Gallyas silver staining and anti-A β antibody Ab5 (anti-Mouse). NFT count is increased in the progression of AD neuropathological changes with a significant increase from low AD and intermediate AD to high AD cases. Sample size- low AD (n = 14), intermediate AD (n = 15), high AD (n = 21), and high AD mixed pathology (n = 20). b NFT/NP ratio in the hippocampus all regions. CA1 region (Low magnification 300 μm) from a high AD case with NP and NFT depicted in high magnification (60 μm). No significant differences in NFT/NP in the hippocampus all regions between AD stages. Sample size- low AD (n = 14), intermediate AD (n = 15), high AD (n = 21), and high AD mixed pathology (n = 19). c NFT/NP ratio in frontal cortex. Frontal cortex (Low magnification 300 μm) from a High AD case with NP and NFT depicted in high magnification (60 μm). No significant differences in NFT/NP between low AD and intermediate AD, but significant increase in NFT/NP from low AD and intermediate AD to high AD. Sample size- low AD (n = 18), intermediate AD (n = 18), high AD (n = 19) and high AD mixed pathology (n = 21). d NFT/NP ratio in occipital cortex. Occipital cortex (Low magnification 300 μm) from a high AD case with NP and NFT depicted in high magnification (60 μm). NFT/NP ratio is significantly increased from low AD and intermediate AD to high AD. Sample size- low AD (n = 16), intermediate AD (n = 19), high AD (n = 23), and high AD mixed pathology (n = 20)